Michael Cawley, BS, PharmD, RRT, CPFT, FCCM, professor of clinical pharmacy at the University of the Sciences, discusses the current guidelines pharmacists should refer to when selecting respiratory medication inhalers and managing asthma and chronic obstructive pulmonary disorder.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Possible side effects for multiple sclerosis medications can range from mild to life-threatening.
The FDA has approved Spectrum Pharmaceuticals' melphalan for 2 new indications for patients with multiple myeloma.
Daniel T. Abazia, PharmD, BCPS, discusses some of the non-pharmacologic treatment options that pharmacists can recommend to patients experiencing opioid-induced constipation.
Patients diagnosed with bipolar disorder are at very high risk for medication nonadherence.
Amid changes in the health care landscape, there is little doubt that technicians are taking on more prominent roles within the pharmacy team.
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses and debunks the myths and hysteria surrounding the use of opioid therapy in treating non-cancer pain.
Greater than 10% of referrals to respiratory specialists are for chronic cough, given the condition's persistent, refractory nature.
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses strategies pharmacists can employ to enhance the safe use of chronic opioid therapy.
The FDA is reviewing Amgen's supplemental biologics license application for the expanded use of etanercept to treat pediatric patients with chronic severe plaque psoriasis.
Most patients understand very little about the amount of social work pharmacists perform on a daily basis.
One of the most under-recognized and under-addressed barriers to safe and effective care is low vision.
Daniel T. Abazia, PharmD, BCPS, outlines some of the factors that might contribute to a patient's propensity to experience opioid-induced constipation.
Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses the effects of expanded naloxone access.
The American Pharmacists Association House of Delegates voted to adopt new policy on the labeling and measurement of oral liquid medications at the recently completed APhA Annual Meeting in Baltimore Maryland.
Seena Haines, PharmD, BCACP, FAPhA, FASHP, BC-ADM, CDE, professor and department chair for Pharmacy Practice, University of Mississippi School of Pharmacy, explains why obesity is considered a chronic disease.
Where does your pharmacy school or alma mater rank among others?
Two Ohio Northern University pharmacy students have received college of psychiatric and neurologic pharmacists (CPNP) grants to attend the CPNP 2016 Annual Meeting.
Are you ready for a career coach and change in pharmacy?
Glaucoma patients typically have ever-changing drug therapy regimens involving multiple eye drop products.
The life of a typical pharmacy student isn't easy.
Susan Cornell, PharmD, CDE, FAPhA, FAADE, offers tips for how pharmacists can monitor for hypoglycemia in type 2 diabetics on second-line therapies.
Pharmacists should keep an eye out for patients with diabetes taking pravastatin and paroxetine concomitantly, as this medication combination could be deadly.
Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses the obstacles that pharmacists are encountering as naloxone access continues to improve.
OptumRx and Walgreens are partnering to create a new pharmacy solution to meet consumers' changing prescription drug needs and help employers, health plans and their members achieve better health outcomes and greater cost savings.
Patients celebrating St. Patrick’s Day while taking medications affected by alcohol are going to have a bad time.
The reversal agent for rocuronium (Zemuron) is creating big buzz among emergency departments and anesthesia suites.
Dennis Williams, PharmD, FAPhA, talks about ways to prevent allergies related to pets and dust.
After finding glass particulate in a vial, Teva Pharmaceuticals is recalling 1 lot of its amikacin sulfate injection USP, 1 gram/4 mL, vials.
